OJVM  Vol.5 No.5 , May 2015
Potent Anticancer Effect of PET-Fraction (PET-F) in Comparison with Other Commercial Products on Canine Cancer Cells
Abstract: A variety of nutritional supplements are commercially available for the potential therapeutic purpose for dogs and other domestic animals with cancers. However, the efficacy of these supplements on those cancer-bearing animals has not been verified and remains uncertain, due to the lack of the sufficient scientific studies/data. To address this important issue, we examined actual anticancer effects of five selected commercial products on the two types of canine cancer models in vitro. Among them, PET-Fraction (PET-F) obtained from maitake mushroom has been shown to have potent anticancer effect on canine cancer cells. In comparison with this PET-F, possible anticancer effects of the rest of four products were examined. Two of four products were found to have the significant anticancer effects on both cancer cells, while other two products had little effects. Nevertheless, PET-F exhibited the best anticancer effect. Cell cycle analysis indicated that the PET- F-induced growth reduction was attributed to a G1 cell cycle arrest, and Western blot analysis further revealed that such a growth reduction was coupled with apoptosis. Moreover, anticancer activity of PET-F was remarkably enhanced with vitamin C, but no such synergistic effect was seen with other four products. Therefore, although two other products besides PET-F yet have anticancer activities, PET-F appears to be the most potent and promising commercial product that can be useful in effectively and safely treating canine cancers.
Cite this paper: Konno, S. and Choudhury, M. (2015) Potent Anticancer Effect of PET-Fraction (PET-F) in Comparison with Other Commercial Products on Canine Cancer Cells. Open Journal of Veterinary Medicine, 5, 101-110. doi: 10.4236/ojvm.2015.55014.

[1]   Richards, K.L. and Suter, S.E. (2015) Man’s Best Friend: What Can Pet Dogs Teach Us about Non-Hodgkin’s Lymphoma? Immunological Reviews, 263, 173-191.

[2]   Davis, B.W. and Ostrander, E.A. (2014) Domestic Dogs and Cancer Research: A Breed-Based Genomics Approach. ILAR Journal, 55, 59-68.

[3]   Mizuno, T. and Zhuang, C. (1995) Maitake, Grifola frondosa: Pharmacological Effects. Food Reviews International, 11, 135-149.

[4]   Nanba, H., Hamaguchi, A. and Kuroda, H. (1987) The Chemical Structure of an Antitumor Polysaccharide in Fruit Bodies of Grifola frondosa (Maitake). Chemical and Pharmaceutical Bulletin, 35, 1162-1168.

[5]   Kabir, Y., Yamaguchi, M. and Kimura, S. (1987) Effect of Shiitake (Lentinus edodes) and Maitake (Grifola frondosa) Mushrooms on Blood Pressure and Plasma Lipids of Spontaneously Hypertensive Rats. Journal of Nutritional Science and Vitaminology (Tokyo), 33, 341-346.

[6]   Adachi, K., Nanba, H., Otsuka, M. and Kuroda, H. (1988) Blood Pressure-Lowering Activity Present in the Fruit Body of Grifola frondosa (Maitake). Chemical and Pharmaceutical Bulletin, 36, 1000-1006.

[7]   Kubo, K., Aoki, H. and Nanba, H. (1994) Anti-Diabetic Activity Present in the Fruit Body of Grifola frondosa (Maitake). Biological and Pharmaceutical Bulletin, 17, 1106-1110.

[8]   Kubo, K. and Nanba, H. (1996) The Effect of Maitake Mushroom on Liver and Serum Lipids. Alternative Therapies in Health and Medicine, 2, 62-66.

[9]   Nakai, R., Masui, H., Horio, H. and Ohtsuru, M. (1999) Effect of Maitake (Grifola frondosa) Water Extract on Inhibition of Adipocyte Conversion of C3H10T1/2B2C1 Cells. Journal of Nutritional Science and Vitaminology (Tokyo), 45, 385-389.

[10]   Gu, C.Q., Li, J.W. and Chao, F.H. (2006) Inhibition of Hepatitis B Virus by D-Fraction from Grifola frondosa: Synergistic Effect of Combination with Interferon-α in HepG2 2.2.15. Antiviral Research, 72, 162-165.

[11]   National Cancer Institute (1992) Developmental Therapeutics Program: In-Vitro Anti-HIV Drug Screening Results. National Science Council F195001, Washington DC.

[12]   Konno, S. (2004) Potential Growth Inhibitory Effect of Maitake-D-Fraction on Canine Cancer Cells. Veterinary Therapeutics, 5, 263-271.

[13]   Mordente, J.A., Konno, S., Chen, Y., Wu, J.M., Tazaki, H. and Mallouh, C. (1998) The Effects of Brefeldin A (BFA) on Cell Cycle Progression Involving the Modulation of the Retinoblastoma Protein (pRB) in PC-3 Prostate Cancer Cells. Journal of Urology, 159, 275-279.

[14]   Sherr, C.J. (2000) The Pezcoller Lecture: Cancer Cell Cycles Revised. Cancer Research, 60, 3689-3695.

[15]   Yip, K.W. and Reed, J.C. (2008) Bcl-2 Family Proteins and Cancer. Oncogene, 27, 6398-6406.

[16]   Morishige, F. (1986) The Role of Vitamin C in Tumor Therapy (Human). In: Meyskens Jr., F.I. and Parasad, K.N., Eds., Vitamins and Cancer: Human Cancer Prevention by Vitamins and Micronutrients, Humana Press, Clifton, 399- 427.

[17]   Cekanova, M. and Rathore, K. (2014) Animal Models and Therapeutic Molecular Targets of Cancer: Utility and Limitations. Drug Design, Development and Therapy, 8, 1911-1922.

[18]   Sayama, A., Okado, K., Imaoka, M., Yokouchi, Y., Jindo, T. and Takasaki, W. (2014) Subcutaneous Soft Tissue Sarcoma with Rhabdoid Features in a Dog. Journal of Toxicologic Pathology, 27, 131-138.

[19]   Griessmayr, P.C., Gauthier, M., Barber, L.G. and Cotter, S.M. (2007) Mushroom-Derived Maitake PET-Fraction as Single Agent for the Treatment of Lymphoma in Dogs. Journal of Veterinary Internal Medicine, 21, 1409-1412.

[20]   Johnston, S.A., Thamm, D.H. and Legutki, J.B. (2014) The Immunosignature of Canine Lymphoma: Characterization and Diagnostic Application. BMC Cancer, 14, 657-667.

[21]   Nippon Zenoaq Kogyo Co. Ltd. (2003) Subacute Toxicity Test of PET-Fraction in Beagle Dogs. Zenoaq Publication, Koriyama, Fukushima.